Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.
BAGSVÆRD, Denmark and PLAINSBORO, N.J., Sept. 29, 2025 /PRNewswire/ -- Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Insulin efsitora was noninferior to once-daily insulins ...
"Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 ...
With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa. Lilly on Sunday ...
Yurpeak is the second tirzepatide brand from Eli Lilly to be launched in the country after receiving approval from the drug regulator.
NDTV Profit on MSN
Ozempic launched in India for type 2 diabetes treatment: Check cost, should you take it for weight loss?
Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with uncontrolled Type 2 diabetes mellitus (T2DM).
In DURATION-1, Drucker et al sought to compare a long-acting-release formulation of exenatide (2 mg, injected once weekly) with 10-µg exenatide injected twice per day in 295 patients with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback